Neuren - Cracking the $200m m/cap again., page-47

If you look at Bell's valuation and remove the probability ratios (assuming P3 success and FDA approval) they have Neuren valued at $800m on Trofinetide for Retts and Fragile X alone. Success of the Trofinetide molecule then adds weight to the potential of NNZ-2591 the value of which needs to be added to the $800m plus the multitude of other potential applications for either drug.

I my view if it isn't $1B minimum then we haven't achieved full value and the board should continue down the P3 path until we do. I would be disappointed if the sold out early for less than this. I think the shareholders have shown they are in for the long haul and we should run the course to unlock full potential.